Arcus Biosciences (RCUS) EBT Margin (2017 - 2026)
Arcus Biosciences (RCUS) recorded quarterly EBT Margin of 752.94% in Q1 2026, down 134.41% quarter-over-quarter from 321.21% in Q4 2025, and down 35294.0% on a YoY basis from N/an in Q1 2025.
Arcus Biosciences (RCUS) EBT Margin (2017 - 2026) Analysis & Trends
Arcus Biosciences' EBT Margin history runs 10 years deep, the most recent figure standing at 752.94% for Q1 2026.
- In Q1 2026, EBT Margin fell 35294.0% year-over-year to 752.94%; the TTM figure through Mar 2026 stood at 156.36% (up 12024.0% YoY), while the FY2025 annual figure was 142.91%, down 3361.0% from the prior year.
- EBT Margin was 752.94% for Q1 2026 at Arcus Biosciences, down from 321.21% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 2.76% in Q1 2024 to a low of 752.94% in Q1 2026.
- Historically, EBT Margin has averaged 322.04% across 5 years, with a median of 283.59% in 2023.
- The sharpest annual moves came in 2022 and 2025: EBT Margin soared 62720 bps in 2022, then tumbled 39724 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 197.06% in 2022, then slumped by 190 bps to 571.43% in 2023, then jumped by 37 bps to 357.69% in 2024, then climbed by 10 bps to 321.21% in 2025, then sank by 134 bps to 752.94% in 2026.
- The last three EBT Margin figures came in at 752.94% (Q1 2026), 321.21% (Q4 2025), and 519.23% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcus Biosciences | 3.05 Bn | 2.23 Bn | - | -752.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -752.94% |
| Dec 31, 2025 | -321.21% |
| Sep 30, 2025 | -519.23% |
| Mar 31, 2025 | -400.00% |
| Dec 31, 2024 | -357.69% |
| Sep 30, 2024 | -191.67% |
| Jun 30, 2024 | -238.46% |
| Mar 31, 2024 | -2.76% |
| Dec 31, 2023 | -571.43% |
| Sep 30, 2023 | -215.63% |
| Jun 30, 2023 | -255.17% |
| Mar 31, 2023 | -312.00% |
| Dec 31, 2022 | -197.06% |
| Sep 30, 2022 | -196.97% |
| Jun 30, 2022 | -248.15% |
| Mar 31, 2022 | -372.22% |
| Dec 31, 2021 | 79.39% |
| Sep 30, 2021 | -824.17% |
| Jun 30, 2021 | -802.98% |
| Mar 31, 2021 | -767.29% |